var data={"title":"Zolpidem: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Zolpidem: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7185?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=zolpidem-drug-information\" class=\"drug drug_general\">see &quot;Zolpidem: Drug information&quot;</a> and <a href=\"topic.htm?path=zolpidem-patient-drug-information\" class=\"drug drug_patient\">see &quot;Zolpidem: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236158\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ambien;</li>\n      <li>Ambien CR;</li>\n      <li>Edluar;</li>\n      <li>Intermezzo;</li>\n      <li>Zolpimist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13452765\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sublinox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1043344\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Hypnotic, Nonbenzodiazepine</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1043377\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=zolpidem-drug-information\" class=\"drug drug_general\">see &quot;Zolpidem: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> The lowest effective dose should be used; higher doses may be more likely to impair next-morning activities.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents &le;17 years: <b>Insomnia:</b> Oral: Limited data available; efficacy results variable and have <b>not</b> been demonstrated in randomized placebo-controlled trials. An open-label, dose escalation pharmacokinetic evaluation showed zolpidem was well-tolerated in pediatric patients 2 to 18 years of age and recommended a dose of 0.25 mg/kg at bedtime for evaluation in future efficacy trials (Blumer 2008). A single case report describes an 18-month-old infant who was effectively treated with zolpidem for primary insomnia (Bhat 2008). However, zolpidem has <b>not</b> been shown to be effective in a randomized placebo-controlled trial (n=201) of children aged 6 to 17 years with ADHD-associated insomnia; zolpidem 0.25 mg/kg/dose (maximum dose: 10 mg) administered nightly did <b>not</b> decrease sleep latency; in addition, hallucinations occurred in 7.4% of patients (Blumer 2009). A comparative, randomized controlled trial of zolpidem and haloperidol in pediatric burn patients (n=40, mean age: 9.4 &plusmn; 0.7 years) showed zolpidem dosed at 0.5 mg/kg nightly for one week (maximum dose: 20 mg) minimally increased Stage 3/4 sleep and REM but not total sleep time; the authors no longer use zolpidem to try to improve sleep in their pediatric burn patients (Armour 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents &ge;18 years and Adults: <b>Insomnia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablet, spray: 5 mg (females) or 5 to 10 mg (males) immediately before bedtime; maximum dose: 10 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablet: 6.25 mg (females) or 6.25 to 12.5 mg (males) immediately before bedtime; maximum dose: 12.5 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Edluar: 5 mg (females) or 5 to 10 mg (males) immediately before bedtime; maximum dose: 10 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermezzo: <b>Note:</b> Should be taken if patient awakens in middle of night, has difficulty returning to sleep, and has at least 4 hours left before waking.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Females: 1.75 mg once per night as needed; maximum dose: 1.75 mg/night</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Males: 3.5 mg once per night as needed; maximum dose: 3.5 mg/night</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosage adjustment with concomitant CNS depressants: Females and males: 1.75 mg once per night as needed; dose adjustment of concomitant CNS depressant(s) may be necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for renal impairment:</b> Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">No dosage adjustment necessary. Use with caution and monitor patients with renal impairment closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Not dialyzable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablet, spray: 5 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablet: 6.25 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Edluar: 5 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermezzo: Females and males: 1.75 mg once per night as needed. <b>Note:</b> Take only if &ge;4 hours left before waking.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236134\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as tartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zolpimist: 5 mg/actuation (4.5 mL, 7.7 mL) [contains benzoic acid, propylene glycol; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as tartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ambien: 5 mg [contains fd&amp;c red #40, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ambien: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as tartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ambien CR: 6.25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ambien CR: 12.5 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6.25 mg, 12.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual, as tartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Edluar: 5 mg, 10 mg [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermezzo: 1.75 mg, 3.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.75 mg, 3.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236119\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236197\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874935\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ambien: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019908s037lbl.pdf#page=22&amp;token=75PsuI+EeUfWlTrJ3gqZANsudOS1cZr8VexmYVuGbVYh8QTVEdj8UN/KrRzFqcRpxQHCUHPr7P+cP1uYdpcrqn/pprBteWVqLa2gv8bG3nooxeb8F38uRkf5NO8LzLxm&amp;TOPIC_ID=13094\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019908s037lbl.pdf#page=22</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ambien CR: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021774s018lbl.pdf#page=24&amp;token=CKPde+Cmbyo2vs9FV6Wx1xkZekKqJ7gTI7vP3Ph2HTnaOGqlT7sHW+8wFX9pI0cQbd9H9eVkxEQT8XLjoOVQ8fua+NbnNB9R7fBXykLqB2DdA0xlu2mU3lsWilG47lku&amp;TOPIC_ID=13094\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021774s018lbl.pdf#page=24</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Edluar: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135937.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQiFnDZrbs/BGuJiptmuAjeg==&amp;TOPIC_ID=13094\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135937.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermezzo: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM281854.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68KmduXd4oyjZ9b8vE0MZPow==&amp;TOPIC_ID=11157\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM281854.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zolpidem:<a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089833.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRl12ZIlF2tdv36w+uFduP1bw==&amp;TOPIC_ID=11157\" target=\"_blank\"> http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089833.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zolpimist: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM143465.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQKahWXH8nO1Kzm8YzUkQrQw==&amp;TOPIC_ID=11157\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM143465.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7727194\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">All formulations (excluding Intermezzo): Administer immediately before bedtime due to rapid onset of action. For faster sleep onset, do not administer with (or immediately after) a meal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablets (Edluar, Intermezzo): Examine blisterpack before use; do not use if blisters are broken, torn, or missing. Separate individual blisters at perforation; peel off top layer of paper; push tablet through foil. Place under the tongue and allow to disintegrate; do not swallow or administer with water. Intermezzo should be taken in bed if patient awakens in the middle of the night and has at least 4 hours left before waking.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral spray (Zolpimist): Spray directly into the mouth over the tongue. Prior to initial use, pump should be primed by spraying 5 times. If pump is not used for at least 14 days, reprime pump with 1 spray. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablets (Ambien CR): Swallow whole; do not divide, crush, or chew. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5659904\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release and sublingual tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect sublingual tablets from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); limited excursions permitted up to 30&deg;C (86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral spray: Store upright at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze. Avoid prolonged exposure to temperatures &gt;30&deg;C (86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet (Sublinox [Canadian product]): Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1043345\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> Tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ambien: Short-term treatment of insomnia (with difficulty of sleep onset) (FDA approved in age &ge;18 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ambien CR: Treatment of insomnia (with difficulty of sleep onset and/or sleep maintenance) (FDA approved in age &ge;18 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Edluar: Short-term treatment of insomnia (with difficulty of sleep onset) (FDA approved in age &ge;18 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermezzo: &quot;As needed&quot; treatment of middle-of-the-night insomnia with &ge;4 hours of sleep time remaining (FDA approved in age age &ge;18 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral spray: Zolpimist: Short-term treatment of insomnia (with difficulty of sleep onset) (FDA approved in age &ge;18 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236204\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ambien may be confused with Abilify, Ativan, Ambi 10</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sublinox may be confused with Suboxone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zolpidem may be confused with lorazepam, zaleplon, Zyloprim</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Zolpidem, a nonbenzodiazepine benzodiazepine-receptor agonist hypnotic, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to adverse events similar to benzodiazepines in older adults (eg, delirium, falls, fractures) and an increase in emergency room visits, hospitalizations, and motor vehicle crashes. In addition, improvement in sleep latency and duration is minimal (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Zolpidem (when cumulative day supply is &gt;90 days) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ambien [US, Argentina, Israel] may be confused with Amyben brand name for amiodarone [Great Britain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236202\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported with oral administration, unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest discomfort, chest pain, edema, hypertension, increased blood pressure, orthostatic hypotension, palpitations, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, agitation, amnesia, anxiety, apathy, ataxia, cerebrovascular disease, cognitive dysfunction, confusion, depersonalization, depression, disinhibition, disorientation, dizziness, drowsiness, drugged feeling, dysarthria, eating disorder (binge eating), emotional lability, equilibrium disturbance, euphoria, falling, fatigue, hallucination, headache (more common in oral), hypoesthesia, illusion, increased body temperature, insomnia, lack of concentration, lethargy, malaise, memory impairment, migraine, nervousness, paresthesia, psychomotor retardation, sleep disorder, speech disturbance, stress, stupor, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pallor, pruritus, skin rash, urticaria, wrinkling of skin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, hypermenorrhea, increased thirst, menstrual disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal tenderness, anorexia, change in appetite, constipation, diarrhea, dysgeusia, dyspepsia, flatulence, frequent bowel movements, gastroenteritis, gastroesophageal reflux disease, hiccups, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis, dysuria, urinary incontinence, urinary tract infection, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, leg cramps, myalgia, neck pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Asthenopia, blurred vision, diplopia, eye irritation, eye pain, eye redness, scleritis, visual disturbance (including altered depth perception)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Labyrinthitis, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, dyspnea, flu-like symptoms, lower respiratory tract infection, pharyngitis, rhinitis, sinusitis, throat irritation, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, trauma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal gait, abnormal lacrimation, abnormality in thinking, abscess, accommodation disturbance, acne vulgaris, acute renal failure, aggressive behavior, alteration of saliva, altered sense of smell, anaphylactic shock, anaphylaxis, anemia, angina pectoris, angioedema (including tongue, glottis, larynx), arteritis, behavioral changes, breast fibroadenosis, breast neoplasm, bronchospasm, bullous rash, cardiac arrhythmia, circulatory shock, conjunctivitis, corneal ulcer, decreased libido, delusions, dementia, dental caries, dermatitis, drug tolerance, dysphagia, dysphasia, enteritis, epistaxis, eructation, esophageal spasm, exacerbation of hypertension, extrasystoles, facial edema, furunculosis, gastritis, glaucoma, gout, hemorrhoids, hepatic encephalopathy (in patients with hepatic insufficiency), hepatitis (mixed pattern, hepatocellular, and cholestatic; with or without jaundice), herpes simplex infection, herpes zoster, hot flash, hyperbilirubinemia, hypercholesteremia, hyperhemoglobinemia, hyperlipidemia, hypokinesia, hypotension, hypotonia, hypoxia, hysteria, impotence, increased appetite, increased blood urea nitrogen, increased erythrocyte sedimentation rate, increased serum alkaline phosphatase, increased serum AST, inflammation at injection site, intestinal obstruction, intoxicated feeling, laryngitis, leukopenia, lymphadenopathy, macrocytic anemia, manic reaction, mastalgia, myasthenia, myocardial infarction, neuralgia, neuritis, neuropathy, nocturia, numbness of tongue, oral bullae (sublingual tablet), oral inflammation (sublingual tablet), oral mucosa ulcer (sublingual tablet), osteoarthritis, pain, otitis externa, otitis media, panic disorder, paresis, periorbital edema, personality disorder, phlebitis, photopsia, pneumonia, polyuria, psychoneurosis, pulmonary edema, pulmonary embolism, purpura, pyelonephritis, rectal hemorrhage, renal pain, respiratory depression, restless leg syndrome, rigors, sciatica, skin photosensitivity, sleep driving, somnambulism, strange feeling, suicidal ideation, suicidal tendencies, tendonitis, tenesmus, tetany, thrombosis, urinary frequency, urinary retention, varicose veins, ventricular tachycardia, weight loss, yawning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236142\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to zolpidem or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Significant obstructive sleep apnea syndrome and acute and/or severe impairment of respiratory function; myasthenia gravis; severe hepatic impairment; personal or family history of sleepwalking</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236123\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abnormal thinking/behavioral changes: Hypnotics/sedatives have been associated with abnormal thinking and behavior changes including decreased inhibition (eg, aggressiveness and extroversion that seemed out of character), bizarre behavior, agitation, visual and auditory hallucinations, and depersonalization. These changes may occur unpredictably and may indicate previously unrecognized psychiatric disorders; evaluate appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression impairing physical and mental capabilities; patients must be cautioned about performing tasks which require mental alertness (operating machinery or driving). An increased risk of next-day psychomotor impairment is increased if patient is unable to stay in bed for a full night of sleep (7 to 8 hours); if coadministered with other CNS depressants and/or taken with other drugs that increase blood levels of zolpidem; or if a higher than recommended dose is taken. Dose adjustment may be necessary if taking concomitant CNS depressants; use with alcohol is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis as well as angioedema, have been reported after taking the first or subsequent doses. Do not rechallenge patient if such reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving, preparing and eating food, making phone calls, or having sex while asleep have also been noted; amnesia, anxiety, and other neuropsychiatric symptoms may also occur. Patients usually do not remember these events. The use of alcohol, other CNS depressants, and exceeding the recommended maximum dose may increase the risk of these activities. Discontinue treatment in patients who report any sleep-driving episodes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with depression; worsening of depression, including suicide or suicidal ideation has been reported with the use of hypnotics. Intentional overdose may be an issue in this population. The minimum dose that will effectively treat the individual patient should be used. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug abuse: Use with caution in patients with a history of drug dependence. Risk of abuse is increased in patients with a history or family history of alcohol or drug abuse or mental illness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: GABA agonists, including zolpidem, have been associated with precipitation of hepatic encephalopathy in patients with hepatic impairment. Patients with hepatic impairment do not clear zolpidem as rapidly as patients with normal hepatic function. Use with caution in patients with mild to moderate hepatic impairment; dose adjustment recommended. Avoid use of immediate and extended-release tablets in patients with severe hepatic impairment; may result in encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory compromise, COPD, or sleep apnea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated: Use with caution in debilitated patients; potential for oversedation, impaired coordination, and confusion with use; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; dose adjustment recommended. Monitor for impaired cognitive and/or motor performance, confusion, and potential for falling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Females: Dosage adjustment is recommended for females; pharmacokinetic studies involving zolpidem showed a significant increase in maximum concentration and exposure in females compared to males at the same dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: When studied for the unapproved use of insomnia associated with ADHD in children, a higher incidence (~7%) of hallucinations was reported. In addition, sleep latency did not decrease compared to placebo.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7 to 10 days may indicate the need for psychiatric and/or medical illness reevaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rapid onset: Because of the rapid onset of action, administer Intermezzo immediately prior to bedtime, after the patient has gone to bed and is having difficulty falling asleep, or during the middle of the night when at least 4 hours are left before waking.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Abrupt discontinuance or rapid dose decrease may lead to withdrawal symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819276\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The most common adverse effects observed in children include the following: Dizziness, headache, hallucinations, affect lability, enuresis, gastroenteritis, and anxiety (Blumer, 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236189\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236128\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13094&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Zolpidem may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.  Management: Monitor zolpidem response closely.  Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving carbamazepine.  No such dose change is recommended for women.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Zolpidem. Management: Consider avoiding the combination of ciprofloxacin and zolpidem if possible. If combined, monitor for signs of zolpidem toxicity (eg, somnolence, dizziness, lethargy).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Zolpidem. Management: Consider using a lower starting dose of zolpidem in patients receiving ketoconazole and monitor for increased zolpidem effects/toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May enhance the sedative effect of Hypnotics (Nonbenzodiazepine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Zolpidem.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Zolpidem.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May decrease the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236154\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Maximum plasma concentration and bioavailability are decreased with food; time to peak plasma concentration is increased; half-life remains unchanged. Grapefruit juice may decrease the metabolism of zolpidem. Management: Do not administer with (or immediately after) a meal. Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236129\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1615032\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Zolpidem crosses the placenta (Juric, 2009). Severe neonatal respiratory depression has been reported when zolpidem was used at the end of pregnancy, especially when used concurrently with other CNS depressants. Children born of mothers taking sedative/hypnotics may be at risk for withdrawal; neonatal flaccidity has been reported in infants following maternal use of sedative/hypnotics during pregnancy. Additional adverse effects to the fetus/newborn have been noted in some studies (Wang, 2010; Wikner, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1043383\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Daytime alertness; respiratory rate; behavior profile </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236122\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Zolpidem, an imidazopyridine hypnotic that is structurally dissimilar to benzodiazepines, enhances the activity of the inhibitory neurotransmitter, &gamma;-aminobutyric acid (GABA), via selective agonism at the benzodiazepine-1 (BZ<sub>1</sub>) receptor; the result is increased chloride conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability leading to sedative and hypnotic effects. Because of its selectivity for the BZ<sub>1</sub> receptor site over the BZ<sub>2</sub> receptor site, zolpidem exhibits minimal anxiolytic, myorelaxant, and anticonvulsant properties (effects largely attributed to agonism at the BZ<sub>2</sub> receptor site). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236141\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immediate release: 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immediate release: 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: C<sub>max</sub> and AUC is increased by ~45% in females compared to male subjects</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release and sublingual: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Biphasic absorption; rapid initial absorption (similar to immediate release product); then provides extended concentrations in the plasma beyond 3 hours postadministration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: 1.8 &plusmn; 0.8 L/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;6 to 12 years: 2.2 &plusmn; 1.7 L/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: 1.2 &plusmn; 0.4 L/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.54 L/kg after an IV dose (Holm 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~93%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic methylation and hydroxylation via CYP3A4 (~60%), CYP2C9 (~22%), CYP1A2 (~14%), CYP2D6 (~3%), and CYP2C19 (~3%) to 3 inactive metabolites (Holm 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Immediate release: 70% (Holm 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: Immediate release: 1.8 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;6 years and Adolescents: Immediate release: 2.3 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release, Extended release: ~2.5 hours (range: 1.4 to 4.5 hours); Cirrhosis: Up to 9.9 hours; Elderly: Prolonged up to 32%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Spray: ~3 hours (range: 1.7 to 8.4)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet: ~3 hours (range: 1.4 to 6.7 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: Immediate release: 0.9 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;6 to 12 years: Immediate release: 1.1 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Immediate release: 1.3 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 1.6 hours; 2.2 hours with food</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: 1.5 hours; 4 hours with food</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Spray: ~0.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet: Edluar: ~1.4 hours, ~1.8 hours with food; Intermezzo: 0.6 to 1.3 hours, ~3 hours with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (48% to 67%, primarily as metabolites); feces (29% to 42%, primarily as metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance, apparent:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: 11.7 &plusmn; 7.9 mL/minute/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;6 to 12 years: 9.7 &plusmn; 10.3 mL/minute/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: 4.8 &plusmn; 2 mL/minute/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Intermezzo: Males: 4 mL/minute/kg; Females: 2.7 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236145\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zolpimist Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/ACT (4.5 mL): $49.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Edluar Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $445.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $445.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Intermezzo Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75 mg (30): $446.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5 mg (30): $446.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Zolpidem Tartrate Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75 mg (30): $301.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5 mg (30): $301.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Ambien CR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.25 mg (100): $2,020.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $2,020.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Zolpidem Tartrate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.25 mg (100): $611.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $611.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ambien Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $2,020.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $2,020.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zolpidem Tartrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $462.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $462.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236146\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adorma (UA);</li>\n      <li>Adormix (CL);</li>\n      <li>Ambien (BB, BM, BS, BZ, GY, JM, PR, SR, TT);</li>\n      <li>Ambien CR (AR, IL);</li>\n      <li>Ambulax-2 (IN);</li>\n      <li>Conyx (KR);</li>\n      <li>Dalparan (ES);</li>\n      <li>Dormeben (CO);</li>\n      <li>Dormizol (AU);</li>\n      <li>Flazinil (EC);</li>\n      <li>Fulsadem (AR);</li>\n      <li>Hypnogen (EE);</li>\n      <li>Ivadal (AT);</li>\n      <li>Jonfa (VN);</li>\n      <li>Lioram (BR);</li>\n      <li>Nidraj (BD);</li>\n      <li>Niotal (IT);</li>\n      <li>Nitrest (BD, IN);</li>\n      <li>Nocte (CR, DO, GT, HN, LK, NI, PA, SV);</li>\n      <li>Nocte Sublingual (AR);</li>\n      <li>Nuo Bin (CN);</li>\n      <li>Nytamel (IE);</li>\n      <li>Sanval (RU);</li>\n      <li>Sleepman (TW);</li>\n      <li>Somidem (AU, MY);</li>\n      <li>Somit (AR, PY, UY);</li>\n      <li>Somnil (CO);</li>\n      <li>Somno (PE);</li>\n      <li>Sove (LK);</li>\n      <li>Stildem (AU);</li>\n      <li>Stilnix (IL);</li>\n      <li>Stilnoct (BE, DK, FI, GB, IE, IS, LU, NL, NO, SE);</li>\n      <li>Stilnox (AU, BF, BG, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DO, EE, ES, ET, FR, GH, GM, GN, GR, GT, HK, HN, HU, ID, IT, JO, KE, KR, KW, LB, LR, LT, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, PA, PE, PH, PK, PL, PT, PY, QA, RO, SA, SC, SD, SK, SL, SN, SV, TN, TR, TW, TZ, UG, VE, VN, ZA, ZM, ZW);</li>\n      <li>Stilnox CR (AU, BR, CO, CR, DO, GT, HK, HN, KR, MY, NI, PA, SG, SV);</li>\n      <li>Sucedal (EC);</li>\n      <li>Vicknox (HK);</li>\n      <li>Ziohex (PH);</li>\n      <li>Zodenox (MY);</li>\n      <li>Zodorm (IL);</li>\n      <li>Zoldem (AT, BD, DE, IE);</li>\n      <li>Zoldox (TW);</li>\n      <li>Zoliprex (LK);</li>\n      <li>Zolmia (ID);</li>\n      <li>Zolnod (IE);</li>\n      <li>Zolnox (PY, UY);</li>\n      <li>Zolpibell (AU);</li>\n      <li>Zolpicin (TW);</li>\n      <li>Zolpid (BD, KR);</li>\n      <li>Zolpinox (DE);</li>\n      <li>Zolpirest (PH);</li>\n      <li>Zolpitop (BE);</li>\n      <li>Zolsana (BG);</li>\n      <li>Zopidem (TW);</li>\n      <li>Zopim (MY, TW);</li>\n      <li>Zorimin (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armour A, Gottschlich MM, Khoury J, et al, &quot;A Randomized, Controlled Prospective Trial of Zolpidem and Haloperidol for Use as Sleeping Agents in Pediatric Burn Patients,&quot; <i>J Burn Care Res</i>, 2008, 29(1):238-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/18182928/pubmed\" target=\"_blank\" id=\"18182928\">18182928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhat T, Pallikaleth SJ, and Shah N, &quot;Primary Insomnia Treated With Zolpidem in an 18-Month Old Child,&quot; <i>Indian J Psychiatry</i>, 2008,50(1):59-60.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Findling RL, Shih WJ, et al, &quot;Controlled Clinical Trial of Zolpidem for the Treatment of Insomnia Associated With Attention-Deficit/Hyperactivity Disorder in Children 6 to 17 Years of Age,&quot; <i>Pediatrics</i>, 2009, 123(5):e770-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/19403468/pubmed\" target=\"_blank\" id=\"19403468\">19403468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Reed MD, Steinberg F, et al, &quot;Potential Pharmacokinetic Basis for Zolpidem Dosing in Children With Sleep Difficulties,&quot; <i>Clin Pharmacol Ther</i>, 2008, 83(4):551-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/17957186/pubmed\" target=\"_blank\" id=\"17957186\">17957186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holm KJ, Goa KL. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. <i>Drugs</i>. 2000;59(4):865-889.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/10804040/pubmed\" target=\"_blank\" id=\"10804040\">10804040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juric S, Newport DJ, Ritchie JC, et al, &quot;Zolpidem (Ambien) in Pregnancy: Placental Passage and Outcome,&quot; <i>Arch Womens Ment Health</i>, 2009, 12(6):441-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/19657707/pubmed\" target=\"_blank\" id=\"19657707\">19657707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang LH, Lin HC, Lin CC, et al,  &quot;Increased Risk of Adverse Pregnancy Outcomes in Women Receiving Zolpidem During Pregnancy,&quot; <i>Clin Pharmacol Ther</i>, 2010, 88(3):369-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/20686480/pubmed\" target=\"_blank\" id=\"20686480\">20686480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wikner BN and K&auml;ll&eacute;n B, &quot;Are Hypnotic Benzodiazepine Receptor Agonists Teratogenic in Humans?&quot; <i>J Clin Psychopharmacol</i>, 2011, 31(3):356-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-pediatric-drug-information/abstract-text/21508851/pubmed\" target=\"_blank\" id=\"21508851\">21508851</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13094 Version 230.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F236158\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13452765\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1043344\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1043377\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F236134\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F236119\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F236197\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874935\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7727194\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F5659904\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1043345\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F236204\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F236202\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F236142\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F236123\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819276\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F236189\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F236128\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F236154\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F236129\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1615032\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1043383\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F236122\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F236141\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F236145\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F236146\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13094|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=zolpidem-drug-information\" class=\"drug drug_general\">Zolpidem: Drug information</a></li><li><a href=\"topic.htm?path=zolpidem-patient-drug-information\" class=\"drug drug_patient\">Zolpidem: Patient drug information</a></li></ul></div></div>","javascript":null}